A top executive at Novo Nordisk (NVO) warned Tuesday that the company’s diabetes therapy Ozempic will likely be selected for the next round of Medicare drug pricing negotiations, which aim to seek discounts for blockbuster meds supplied to the federal healthcare program.

Ozempic, the blockbuster diabetes shot made by Novo Nordisk A/S, is “very likely” to be one of the next drugs targeted for a price cut in bargaining with the US government’s Medicare program, a company executive said.

This news of Ozempic price cuts comes on the heels, or tablet, of Novo Nordisk developing a weight loss pill that mirrors the effects of Ozempic. According to new trial results, the pharmaceutical company says Amycretin can cause weight loss of up to 13% in three months.

Americans are paying more than $900 a month for popular weight-loss drugs Ozempic and Wegovy, but drugmakers want to sell generic versions of the drugs for

In August 2023, the U.S. Department of Health and Human Services announced the first 10 drugs covered under Medicare Part D for the first cycle of negotiations.

U.S. Senator Bernie Sanders said on Tuesday he received confirmation from major generic pharmaceutical companies that they could sell copycat versions of Novo Nordisk's diabetes drug Ozempic for less than $100 a month.

Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, may be about to get cheaper. Ozempic dose. The type 2 diabetes drug, which can also cause weight loss, ma